A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer
- PMID: 35667246
- PMCID: PMC9168196
- DOI: 10.1016/j.redox.2022.102358
A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer
Erratum in
-
Corrigendum to "A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer" [Redox Biol. 54 (2022) 102358].Redox Biol. 2022 Aug;54:102393. doi: 10.1016/j.redox.2022.102393. Epub 2022 Jul 3. Redox Biol. 2022. PMID: 35794066 Free PMC article. No abstract available.
Abstract
The redox regulator NRF2 is hyperactivated in a large percentage of non-small cell lung cancer (NSCLC) cases, which is associated with chemotherapy and radiation resistance. To identify redox vulnerabilities for KEAP1/NRF2 mutant NSCLC, we conducted a CRISPR-Cas9-based negative selection screen for antioxidant enzyme genes whose loss sensitized cells to sub-lethal concentrations of the superoxide (O2•-) -generating drug β-Lapachone. While our screen identified expected hits in the pentose phosphate pathway, the thioredoxin-dependent antioxidant system, and glutathione reductase, we also identified the mitochondrial superoxide dismutase 2 (SOD2) as one of the top hits. Surprisingly, β-Lapachone did not generate mitochondrial O2•- but rather SOD2 loss enhanced the efficacy of β-Lapachone due to loss of iron-sulfur protein function, loss of mitochondrial ATP maintenance and deficient NADPH production. Importantly, inhibition of mitochondrial electron transport activity sensitized cells to β-Lapachone, demonstrating that these effects may be translated to increase ROS sensitivity therapeutically.
Keywords: KEAP1; NADPH; NFE2L2; NSCLC; ROS; SOD2; β-Lapachone.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.Redox Biol. 2020 Feb;30:101440. doi: 10.1016/j.redox.2020.101440. Epub 2020 Jan 23. Redox Biol. 2020. PMID: 32007910 Free PMC article.
-
Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling.Free Radic Biol Med. 2022 Feb 20;180:52-62. doi: 10.1016/j.freeradbiomed.2021.12.314. Epub 2021 Dec 30. Free Radic Biol Med. 2022. PMID: 34973363
-
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.Cancer Res. 2019 Jul 1;79(13):3251-3267. doi: 10.1158/0008-5472.CAN-18-3527. Epub 2019 Apr 30. Cancer Res. 2019. PMID: 31040157 Free PMC article.
-
Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.J Thorac Oncol. 2021 Mar;16(3):395-403. doi: 10.1016/j.jtho.2020.11.015. Epub 2020 Dec 8. J Thorac Oncol. 2021. PMID: 33307193 Review.
-
Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks.Theranostics. 2023 Jan 1;13(2):704-723. doi: 10.7150/thno.80184. eCollection 2023. Theranostics. 2023. PMID: 36632216 Free PMC article. Review.
Cited by
-
Applications of CRISPR screening to lung cancer treatment.Front Cell Dev Biol. 2023 Dec 15;11:1295555. doi: 10.3389/fcell.2023.1295555. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38169973 Free PMC article. Review.
-
Reactive Oxygen Species: A Double-Edged Sword in the Modulation of Cancer Signaling Pathway Dynamics.Cells. 2025 Aug 6;14(15):1207. doi: 10.3390/cells14151207. Cells. 2025. PMID: 40801639 Free PMC article. Review.
-
A tandem activity-based sensing and labeling strategy reveals antioxidant response element regulation of labile iron pools.Proc Natl Acad Sci U S A. 2024 Jul 9;121(28):e2401579121. doi: 10.1073/pnas.2401579121. Epub 2024 Jul 5. Proc Natl Acad Sci U S A. 2024. PMID: 38968123 Free PMC article.
-
Pharmacological Inhibition of TXNRD1 by a Small Molecule Flavonoid Butein Overcomes Cisplatin Resistance in Lung Cancer Cells.Biol Trace Elem Res. 2025 Apr;203(4):1949-1960. doi: 10.1007/s12011-024-04331-0. Epub 2024 Aug 14. Biol Trace Elem Res. 2025. PMID: 39141196
-
Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC.Cancer Med. 2024 Apr;13(7):e7021. doi: 10.1002/cam4.7021. Cancer Med. 2024. PMID: 38562019 Free PMC article.
References
-
- Herbst R.S., Morgensztern D., Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials